0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-333.53%PremiumDec 20, 2024Expiry Date5.77Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.30Leverage Ratio--Theta--Rho--Eff Leverage--Vega
iCAD Inc Stock Discussion
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024
iCAD announces major developments at RSNA 2024, including its FDA-cleared ProFound Detection Version 4.0 and a partnership with Cascaid Health.
The collaboration will launch ProFound Health in Q1 2025, offering AI-powered second-read mammography services to expand access to breast health technology. The new Version 4.0...
NEWS
iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium
iCAD, Inc. announces partnership with Densitas and showcases ProFound Cloud at SBI symposium, highlighting advancements in breast cancer detection technology
NASHUA, N.H., April 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will sh...
NEWS
iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting
No comment yet